U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional)

The summary for the U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to continue the U.S.-South Africa Program for Collaborative Biomedical Research into Phase 2. Research areas supported under this program include HIV/AIDS and HIV/AIDS-associated malignancies. This opportunity is specifically designed to promote partnerships between eligible NIH Intramural Research Program (IRP) investigators (e.g. those conducting research within the laboratories and clinics of the NIH) and eligible South African investigators (e.g., those conducting research in eligible laboratories in South Africa). In order to be eligible for this program, the application must include at least one NIH IRP investigator serving as a Project Scientist with an equal role in the conceptualization, design and execution of the research.
Federal Grant Title: U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health Income Security and Social Services
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-AI-19-023
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.393, 93.394, 93.395, 93.396, 93.399, 93.855, 93.865
CFDA Descriptions: Information not provided
Current Application Deadline: July 26th, 2019
Original Application Deadline: July 26th, 2019
Posted Date: March 15th, 2019
Creation Date: March 15th, 2019
Archive Date: August 31st, 2019
Total Program Funding:
Maximum Federal Grant Award: $250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: March 15th, 2019
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Only non-domestic entities that are National Research Foundations (as defined below) from South Africa are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-19-023.html
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (...
Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (...
NIA Program Project Applications (P01 Clinical Trial Optional)
Comprehensive Alcohol Research Centers (P60 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com